Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | EXEC. VP AND CLO | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,272 |
Ending reported balance
After 2026-10-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-09 · Exercise / conversion · Acquired 192 · Balance 105,464 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Row 2 · 2026-10-09 · Sale · Disposed 192 · Balance 105,272 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.42 · Expires 2033-01-04 | Direct | 2,267 |
Reported balance
After 2026-10-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-09 · Exercise / conversion · Disposed 192 · Balance 2,267 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 13, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 192 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001578852-26-000026 · form4-10132026_051001.xml · derivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,267 Underlying: Common Stock · 192 shares Expires 2033-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| October 09, 2026 Filed Oct 13, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 192 | $64.26 | $12,337.92 |
DisclosureSEC source: 0001578852-26-000026 · form4-10132026_051001.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,272 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 09, 2026 Filed Oct 13, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 192 | $39.42 | $7,568.64 |
DisclosureSEC source: 0001578852-26-000026 · form4-10132026_051001.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| October 06, 2026 Filed Oct 7, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 435 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001578852-26-000024 · form4-10072026_051001.xml · derivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,459 Underlying: Common Stock · 435 shares Expires 2033-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F4 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| October 06, 2026 Filed Oct 7, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 435 | $64.16 | $27,909.60 |
DisclosureSEC source: 0001578852-26-000024 · form4-10072026_051001.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,272 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.90 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 06, 2026 Filed Oct 7, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 435 | $39.42 | $17,147.70 |
DisclosureSEC source: 0001578852-26-000024 · form4-10072026_051001.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,638 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001578852-26-000024 · form4-10072026_051001.xml · derivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,894 Underlying: Common Stock · 1,638 shares Expires 2033-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F4 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,638 | $64.03 | $104,881.14 |
DisclosureSEC source: 0001578852-26-000024 · form4-10072026_051001.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,272 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.34 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,638 | $39.42 | $64,569.96 |
DisclosureSEC source: 0001578852-26-000024 · form4-10072026_051001.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,813 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001578852-26-000022 · form4-08192026_050801.xml · derivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,876 Underlying: Common Stock · 2,813 shares Expires 2034-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F4 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 969 | $72.90 | $70,640.10 |
DisclosureSEC source: 0001578852-26-000022 · form4-08192026_050801.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,272 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $72.73 to $73.02 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,844 | $72.39 | $133,487.16 |
DisclosureSEC source: 0001578852-26-000022 · form4-08192026_050801.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,241 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $71.72 to $72.67 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,813 | $25.69 | $72,265.97 |
DisclosureSEC source: 0001578852-26-000022 · form4-08192026_050801.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,813 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001578852-26-000020 · form4-07082026_050704.xml · derivative · entry 12 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock · 2,813 shares Expires 2035-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F7 · derivative.exercise_date: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,226 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001578852-26-000020 · form4-07082026_050704.xml · derivative · entry 11 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,532 Underlying: Common Stock · 2,266 shares Expires 2033-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F6 · derivative.exercise_date: This option was granted on January 5, 2023 and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 745 | $86.38 | $64,353.10 |
DisclosureSEC source: 0001578852-26-000020 · form4-07082026_050704.xml · nonDerivative · entry 10 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,272 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.18 to $86.73 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 645 | $85.84 | $55,366.80 |
DisclosureSEC source: 0001578852-26-000020 · form4-07082026_050704.xml · nonDerivative · entry 9 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,017 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.18 to $86.17 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,036 | $84.41 | $87,448.76 |
DisclosureSEC source: 0001578852-26-000020 · form4-07082026_050704.xml · nonDerivative · entry 8 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,662 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $83.98 to $84.94 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 387 | $83.10 | $32,159.70 |
DisclosureSEC source: 0001578852-26-000020 · form4-07082026_050704.xml · nonDerivative · entry 7 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,698 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $82.76 to $83.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,813 | $46.54 | $130,917.02 |
DisclosureSEC source: 0001578852-26-000020 · form4-07082026_050704.xml · nonDerivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 601 | $86.38 | $51,914.38 |
DisclosureSEC source: 0001578852-26-000020 · form4-07082026_050704.xml · nonDerivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,272 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.18 to $86.73 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 519 | $85.84 | $44,550.96 |
DisclosureSEC source: 0001578852-26-000020 · form4-07082026_050704.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,873 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.18 to $86.17 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 833 | $84.41 | $70,313.53 |
DisclosureSEC source: 0001578852-26-000020 · form4-07082026_050704.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,392 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $83.98 to $84.94 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 313 | $83.10 | $26,010.30 |
DisclosureSEC source: 0001578852-26-000020 · form4-07082026_050704.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,225 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $82.76 to $83.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,266 | $39.42 | $89,325.72 |
DisclosureSEC source: 0001578852-26-000020 · form4-07082026_050704.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,012 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001578852-26-000018 · form4-06222026_050601.xml · derivative · entry 8 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,938 Underlying: Common Stock · 2,012 shares Expires 2035-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F5 · derivative.exercise_date: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,510 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001578852-26-000018 · form4-06222026_050601.xml · derivative · entry 7 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,950 Underlying: Common Stock · 8,510 shares Expires 2035-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F5 · derivative.exercise_date: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 309 | $79.25 | $24,488.25 |
DisclosureSEC source: 0001578852-26-000018 · form4-06222026_050601.xml · nonDerivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,272 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.00 to $79.48 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,703 | $78.50 | $133,685.50 |
DisclosureSEC source: 0001578852-26-000018 · form4-06222026_050601.xml · nonDerivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,581 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.00 to $78.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,012 | $46.54 | $93,638.48 |
DisclosureSEC source: 0001578852-26-000018 · form4-06222026_050601.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,850 | $79.24 | $146,594.00 |
DisclosureSEC source: 0001578852-26-000018 · form4-06222026_050601.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,272 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.00 to $79.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 6,600 | $78.50 | $518,100.00 |
DisclosureSEC source: 0001578852-26-000018 · form4-06222026_050601.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,122 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.00 to $78.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 8,510 | $46.54 | $396,055.40 |
DisclosureSEC source: 0001578852-26-000018 · form4-06222026_050601.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| May 15, 2026 Filed May 19, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,812 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001578852-26-000016 · form4-05192026_050501.xml · derivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,689 Underlying: Common Stock · 2,812 shares Expires 2034-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F4 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. Read SEC document |
| May 15, 2026 Filed May 19, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 456 | $72.67 | $33,137.52 |
DisclosureSEC source: 0001578852-26-000016 · form4-05192026_050501.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,212 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $72.41 to $72.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2026 Filed May 19, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,356 | $72.08 | $169,820.48 |
DisclosureSEC source: 0001578852-26-000016 · form4-05192026_050501.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,668 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $71.41 to $72.29 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2026 Filed May 19, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,812 | $25.69 | $72,240.28 |
DisclosureSEC source: 0001578852-26-000016 · form4-05192026_050501.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| May 08, 2026 Filed May 12, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001578852-26-000014 · form4-05122026_050501.xml · derivative · entry 8 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,460 Underlying: Common Stock · 800 shares Expires 2035-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F5 · derivative.exercise_date: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. Read SEC document |
| May 08, 2026 Filed May 12, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,740 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001578852-26-000014 · form4-05122026_050501.xml · derivative · entry 7 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,260 Underlying: Common Stock · 2,740 shares Expires 2035-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F5 · derivative.exercise_date: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. Read SEC document |
| May 08, 2026 Filed May 12, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 600 | $79.28 | $47,568.00 |
DisclosureSEC source: 0001578852-26-000014 · form4-05122026_050501.xml · nonDerivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,212 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.02 to $79.52 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 08, 2026 Filed May 12, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 200 | $78.00 | $15,600.00 |
DisclosureSEC source: 0001578852-26-000014 · form4-05122026_050501.xml · nonDerivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,812 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| May 08, 2026 Filed May 12, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 800 | $46.54 | $37,232.00 |
DisclosureSEC source: 0001578852-26-000014 · form4-05122026_050501.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| May 08, 2026 Filed May 12, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,900 | $79.31 | $150,689.00 |
DisclosureSEC source: 0001578852-26-000014 · form4-05122026_050501.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,212 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.03 to $79.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 08, 2026 Filed May 12, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 840 | $78.23 | $65,713.20 |
DisclosureSEC source: 0001578852-26-000014 · form4-05122026_050501.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,112 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.00 to $78.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 08, 2026 Filed May 12, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,740 | $46.54 | $127,519.60 |
DisclosureSEC source: 0001578852-26-000014 · form4-05122026_050501.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,265 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001578852-26-000012 · form4-04082026_050401.xml · derivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,798 Underlying: Common Stock · 2,265 shares Expires 2033-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F4 · derivative.exercise_date: This option was granted on January 5, 2023 and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,443 | $69.75 | $100,649.25 |
DisclosureSEC source: 0001578852-26-000012 · form4-04082026_050401.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,212 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $69.30 to $70.25 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 822 | $68.91 | $56,644.02 |
DisclosureSEC source: 0001578852-26-000012 · form4-04082026_050401.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,655 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.24 to $69.17 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,265 | $39.42 | $89,286.30 |
DisclosureSEC source: 0001578852-26-000012 · form4-04082026_050401.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 590 | $69.82 | $41,193.80 |
DisclosureSEC source: 0001578852-26-000010 · form4-02232026_050201.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,212 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $69.52 to $70.18 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.